Breast Cancer Risk Reduction: Current Status and Emerging Trends to Increase Efficacy and Reduce Toxicity of Preventive Medication

Seema Ahsan Khan

doi:10.1016/j.soc.2023.05.001

Breast Cancer Risk Reduction: Current Status and Emerging Trends to Increase Efficacy and Reduce Toxicity of Preventive Medication

Surg Oncol Clin N Am. 2023 Oct;32(4):631-646. doi: 10.1016/j.soc.2023.05.001. Epub 2023 Jun 15.

Author

Seema Ahsan Khan¹

Affiliation

¹ Department of Surgery, Feinberg School of Medicine of Northwestern University, 303 East Superior Street, Chicago, IL 60614, USA. Electronic address: s-khan2@northwestern.edu.

PMID: 37714633
DOI: 10.1016/j.soc.2023.05.001

Abstract

The primary prevention of breast cancer is a worthwhile goal for which the efficacy of antiestrogens is well established. However, implementation has been problematic related to low prioritization by providers and the reluctance of high-risk women to experience medication side effects. Emerging solutions include improved risk estimation through the use of polygenic risk scores and the application of radiomics to screening mammograms; and optimization of medication dose to limit toxicity. The identification of agents to prevent estrogen receptor negative or HER2-positive tumors is being pursued, but personalization of medical risk reduction requires the prediction of tumor subtypes.

Keywords: Antiestrogens; Breast cancer; Primary prevention; Risk estimation.

Publication types

Review

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Breast Neoplasms* / prevention & control
Drug-Related Side Effects and Adverse Reactions*
Female
Humans
Mammography
Risk Factors
Risk Reduction Behavior